The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
Open Access
- 7 October 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 558932
Abstract
Since type and duration of an appropriate adjuvant chemotherapy in early-stage ovarian cancer (OC) are still being debated, novel markers for a better stratification of these patients are of utmost importance for the design of an improved chemotherapeutical strategy. In contrast to numerous cancer studies on cellular proliferation based on the immunohistochemistry-driven evaluation of protein expression, we compared mRNA and protein expression of two independent markers of cellular proliferation, Ki-67 and Plk1, in a large cohort of 243 early-stage OC and their relationship with clinicopathological features and survival. Based on marker expression we demonstrate that early-stage OC patients (stages I/II, low-grade, serous) with high expression (Ki-67, Plk1) had a significantly shorter progression-free survival (PFS) and overall survival (OS) compared to patients with low expression (Ki-67, Plk1). Remarkably, based on mRNA expression this significant difference got lost in advanced stages (III/IV): At least for PFS, high levels of Ki-67 and Plk1 correlate with moderately better survival compared to patients with low expressing tumors. Our data suggest that in addition to Ki-67, Plk1 is a novel marker for the stratification of early-stage OC patients to maximize therapeutic efforts. Both, Ki-67 and Plk1, seem to be better suited in early-stages (I/II) as therapeutical targets compared to advanced-stages (III/IV) OC.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
- Adolf Messer Stiftung
- Deutsche Krebshilfe
- Deutschen Konsortium für Translationale Krebsforschung
This publication has 58 references indexed in Scilit:
- Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cellsNature Communications, 2011
- Ki-67 as a Molecular Target for Therapy in anIn vitroThree-Dimensional Model for Ovarian CancerCancer Research, 2010
- Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal CancerThe American Journal of Pathology, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized TrialJNCI: Journal of the National Cancer Institute, 2010
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLOS Medicine, 2008
- Prognostic factors for high‐risk early‐stage epithelial ovarian cancerCancer, 2008
- The Clinical Importance of Ki-67, p16, p14, and p57 Expression in Patients With Advanced Ovarian CarcinomaInternational Journal of Gynecological Pathology, 2007
- Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)European Journal of Cancer, 2006
- Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinomaThe Lancet, 2001